Portal, founded in 2023, is a biotechnology startup based in the United States. The company focuses on cell engineering and cell analytics across research and clinical applications, with a simplified approach to intracellular delivery. This approach is aimed at accelerating advances enabled by RNA, gene editing, and AI-driven technologies. The company's proprietary mechanical delivery system is capable of delivering various cargo types to a broad range of cell types, offering the potential to impact biological research and cellular therapeutics significantly.
The company recently secured a $5.00M Pre Seed Round investment on 19 March 2024 from investors including Conscience, Pear Ventures, and 10x Capital.
Portal's innovative approach to cell engineering and delivery, coupled with its strong investor backing, positions the company as a promising player in the biotechnology industry. The potential impact of its technology on biological research and cellular therapeutics presents an exciting opportunity for further growth and development in the future.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Pre Seed Round | $5.00M | 3 |
|
19 Mar 2024 |
No recent news or press coverage available for Portal.
We care about your data, and we'd love to use cookies make your experience better.
